Bone Biologics Corporation (BBLG) — This stock currently has no analyst coverage. No price targets, ratings, or earnings estimates are available. This is common for preferred shares, warrants, OTC-traded securities, and smaller companies that are not followed by Wall Street analysts.
Los analistas estiman Beneficio por acción (EPS) de $-19.02 y ingresos de $0.00B para el próximo año fiscal.
Historial de Beneficio por acción (EPS): 2024: real $-4.83 vs est $-19.02 (superó +74.6%). 2025: real $-2.65 vs est $-2.36 (no alcanzó -12.3%). Precisión del analista: 0%.
